Developer docs
API playgroundTry for free, no card

Search company profiles

Parasym

Full company profile

uuid0006nov

Namestring
Parasym
Legal namestring
Parasym
Websiteurl
parasym.co
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Parasym is a London-based neurotechnology company developing non-invasive auricular vagus nerve stimulation (aVNS) technology delivered through a wearable ear-electrode device. The company's proprietary approach stimulates the left tragus to modulate the parasympathetic ("rest-and-digest") nervous system, with claimed effects including increased heart rate variability (61.9% within 5 minutes), learning acquisition gains (57% in a controlled neurolinguistic study), reduction in atrial fibrillation burden (85% in paroxysmal AF patients), and modulation of anti-tumor immune responses in preclinical cancer models. The technology is supported by 60+ completed clinical studies, 100+ ongoing trials, and collaborations with research institutions including UCLA and the University of Chicago, with cumulative R&D investment stated at $10M+ over 10+ years.

The commercial product is the Nuropod, a $900 wearable device sold direct-to-consumer through the parasym.com e-commerce storefront in the U.S. market, with a separate Parasym Performance sub-brand (performance.parasym.com) targeting athletes and high-performers. The company also engages elite sports organizations, national Special Forces programs, and a network of 150+ research institutions, with researchers and healthcare professionals directed to apply for clinical and research access. Revenue mechanics center on one-time hardware sales; the institutional/access channel's pricing model is not publicly disclosed. Operations span London (HQ), Sacramento, and Tallinn, with a team of 1-10 employees.

Short descriptiontext

Parasym is a London-based neurotechnology company that develops and sells the Nuropod, a $900 non-invasive wearable auricular vagus nerve stimulator, serving consumers, elite athletes, healthcare researchers, and defense programs via DTC e-commerce and institutional partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vagus nerve stimulation, wearable neurostimulation devices, non-invasive neuromodulation, auricular nerve therapy, autonomic nervous system devices
Industry2 codes
PRIMARYCRACAQAL
Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Wearable Neurostimulation Devices
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Nuropod Device Sales
TypeHardware Sales
Description

Parasym sells its Nuropod wearable vagus nerve stimulator as a one-time hardware purchase. The device is priced at $900 and is sold directly to consumers in the U.S. market.

gizmodo.com
2Research and Clinical Access
TypeLicensing Royalties
Description

Parasym provides access to its research and clinical data to researchers and healthcare professionals upon application. The revenue mechanics of this channel (licensing, data access fees, or professional services) are not fully specified.

parasym.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Pricing details1 tier
1Nuropod Consumer Device
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$900 one-time purchase for the Nuropod wearable vagus nerve stimulator, available in the U.S.

gizmodo.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Nuropod
Description

Wearable vagus nerve stimulator device designed to reduce stress and enhance recovery through auricular VNS stimulation.

parasym.com
+1 more record
Core offering1 text field

Parasym develops and sells non-invasive wearable auricular vagus nerve stimulation (aVNS) devices, with the flagship Nuropod priced at $900. The device delivers gentle electrical pulses via electrodes placed on the left tragus of the ear to modulate the parasympathetic nervous system, targeting stress reduction, recovery, HRV improvement, sleep quality, and inflammation reduction for consumers, athletes, and clinical researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 57% improvement in learning acquisition (long-term retention of learned second-language vocabulary at 7-day recall vs. placebo)
+4 more records
Product overview1 text field

Parasym offers a portfolio of non-invasive vagus nerve stimulation devices focused on neuromodulation for health and performance. The core product is the Nuropod wearable device, a $900 vagus nerve stimulator that delivers gentle electrical pulses via electrodes on the left tragus. The company also offers Parasym Performance as a sub-brand targeting athletes and high performers seeking enhanced recovery, HRV improvement, and autonomic nervous system regulation. The technology platform is grounded in over 60 clinical studies and partnerships with institutions including UCLA and the University of Chicago.

Product and service2 records
1Nuropod
CategoryWearable Neurostimulation Device
Description

A wearable vagus nerve stimulator designed to reduce stress by delivering gentle electrical pulses through electrodes placed on the left tragus of the ear. It stimulates the vagus nerve to enhance recovery, autonomic nervous system regulation, HRV improvement, sleep quality, and inflammation reduction.

2Parasym Performance
CategoryPerformance Neurostimulation Sub-brand
Description

A sub-brand offering focused on performance optimization, enabling users to command calm and perform on demand through targeted vagus nerve stimulation for athletes and high performers seeking enhanced recovery and autonomic regulation.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parasym developed its Nuropod vagus nerve stimulation technology in partnership with UCLA, one of the world's leading research universities. UCLA's involvement provides academic credibility and research infrastructure supporting the device's clinical validation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parasym developed its technology in partnership with the University of Chicago, contributing research expertise to the clinical validation of its auricular vagus nerve stimulation device.

3150+ Elite Research Institutions
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parasym is trusted by 150+ internationally recognized institutions that serve as research and clinical trial partners. These partnerships span elite universities, sports organizations, and national programs. The company conducts 100+ ongoing clinical studies across all major health and performance applications through these partnerships.

parasym.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

electroCore manufactures gammaCore, a non-invasive vagus nerve stimulation (nVNS) device cleared for migraine, cluster headache, and certain autonomic indications. It is the closest direct competitor to Parasym in portable, non-invasive VNS hardware and is pursuing overlapping clinical and consumer applications.

2Neuvana
TypeDirect peer
Description

Neuvana markets a consumer non-invasive vagus nerve stimulation earbud product aimed at stress relief, relaxation, and focus. It is the closest direct peer to Parasym on the consumer/aVNS side, with a similar product form factor and stress/wellness value proposition.

TypeBroad incumbent
Description

LivaNova's VNS Therapy is the established, implanted vagus nerve stimulation system for drug-resistant epilepsy and depression. It is the broad incumbent in the VNS category and defines the surgical standard that Parasym's non-invasive platform positions against.

TypeEmerging player
Description

Cefaly produces an external trigeminal nerve stimulation device FDA-cleared for migraine prevention and acute treatment. It is an emerging player in the consumer-prescription neurostimulation space, with overlapping non-invasive cranial stimulation use cases and customer profiles.

5Apollo Neuroscience
TypeDirect peer
Description

Apollo Neuroscience builds a wearable device that uses gentle vibrations to influence the autonomic nervous system, targeting stress, sleep, and focus. It targets the same primary consumer segment (stress and HRV regulation) as Parasym and competes for the same DTC wellness buyer.

TypeEmerging player
Description

Muse produces a consumer EEG brain-sensing headband for meditation, focus, and sleep. It is an emerging player in the consumer neurotechnology category, addressing overlapping mental wellness and nervous system regulation outcomes for a similar affluent wellness buyer.

TypeOthers
Description

WHOOP is a performance wearable focused on recovery, strain, sleep, and HRV tracking, with strong penetration into professional sports and high-performance consumers. It is adjacent to Parasym, competing for the same elite-athlete and high-performer wallet but via biometric tracking rather than neurostimulation.

TypeOthers
Description

Oura produces a smart ring focused on sleep, readiness, HRV, and stress insights for consumers and enterprise wellness programs. It is adjacent infrastructure for the same consumer stress/wellness category and competes for placement in employer benefit and performance programs.

TypeOthers
Description

Therabody (maker of Theragun percussive therapy devices) sells recovery and performance hardware into the same elite sports, fitness, and high-performer customer base as Parasym. It is an adjacent recovery-tech brand rather than a direct competitor, but it competes for the same performance dollar.

TypeEmerging player
Description

Dreem builds a sleep-focused EEG headband with neurofeedback and stimulation capabilities, targeting sleep quality and stress reduction. It is an emerging player in consumer neurotechnology, with overlapping use cases in sleep, HRV, and nervous system regulation that intersect with Parasym's value proposition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Parasym

Wearable Neurostimulation Devicesparasym.co

Parasym is a London-based neurotechnology company that develops and sells the Nuropod, a $900 non-invasive wearable auricular vagus nerve stimulator, serving consumers, elite athletes, healthcare researchers, and defense programs via DTC e-commerce and institutional partnerships.

What Parasym does

Parasym is a London-based neurotechnology company developing non-invasive auricular vagus nerve stimulation (aVNS) technology delivered through a wearable ear-electrode device. The company's proprietary approach stimulates the left tragus to modulate the parasympathetic ("rest-and-digest") nervous system, with claimed effects including increased heart rate variability (61.9% within 5 minutes), learning acquisition gains (57% in a controlled neurolinguistic study), reduction in atrial fibrillation burden (85% in paroxysmal AF patients), and modulation of anti-tumor immune responses in preclinical cancer models. The technology is supported by 60+ completed clinical studies, 100+ ongoing trials, and collaborations with research institutions including UCLA and the University of Chicago, with cumulative R&D investment stated at $10M+ over 10+ years.

The commercial product is the Nuropod, a $900 wearable device sold direct-to-consumer through the parasym.com e-commerce storefront in the U.S. market, with a separate Parasym Performance sub-brand (performance.parasym.com) targeting athletes and high-performers. The company also engages elite sports organizations, national Special Forces programs, and a network of 150+ research institutions, with researchers and healthcare professionals directed to apply for clinical and research access. Revenue mechanics center on one-time hardware sales; the institutional/access channel's pricing model is not publicly disclosed. Operations span London (HQ), Sacramento, and Tallinn, with a team of 1-10 employees.

Parasym firmographics

Firmographics
Name
Parasym
Legal name
Parasym
Website
https://parasym.co
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Parasym is a London-based neurotechnology company that develops and sells the Nuropod, a $900 non-invasive wearable auricular vagus nerve stimulator, serving consumers, elite athletes, healthcare researchers, and defense programs via DTC e-commerce and institutional partnerships.
Ownership category
akta.pro rank

Parasym industry classification

Industry
Product category
Wearable Neurostimulation Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYCRACAQAL
Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Vagus nerve stimulation
  • Wearable neurostimulation devices
  • Non-invasive neuromodulation
  • Auricular nerve therapy
  • Autonomic nervous system devices

Where Parasym is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Parasym business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Nuropod Device Sales: Parasym sells its Nuropod wearable vagus nerve stimulator as a one-time hardware purchase. The device is priced at $900 and is sold directly to consumers in the U.S. market.
  2. Research and Clinical Access: Parasym provides access to its research and clinical data to researchers and healthcare professionals upon application. The revenue mechanics of this channel (licensing, data access fees, or professional services) are not fully specified.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goNuropod Consumer Device

Go-to-market motion3 records

Distribution channels2 records

Marketing channels4 records

Parasym product offering

Product offering

Core offering

Parasym develops and sells non-invasive wearable auricular vagus nerve stimulation (aVNS) devices, with the flagship Nuropod priced at $900. The device delivers gentle electrical pulses via electrodes placed on the left tragus of the ear to modulate the parasympathetic nervous system, targeting stress reduction, recovery, HRV improvement, sleep quality, and inflammation reduction for consumers, athletes, and clinical researchers.

Product overview

Parasym offers a portfolio of non-invasive vagus nerve stimulation devices focused on neuromodulation for health and performance. The core product is the Nuropod wearable device, a $900 vagus nerve stimulator that delivers gentle electrical pulses via electrodes on the left tragus. The company also offers Parasym Performance as a sub-brand targeting athletes and high performers seeking enhanced recovery, HRV improvement, and autonomic nervous system regulation. The technology platform is grounded in over 60 clinical studies and partnerships with institutions including UCLA and the University of Chicago.

Differentiator

Problem solved

Functional benefit

Brands

  • Nuropod: Wearable vagus nerve stimulator device designed to reduce stress and enhance recovery through auricular VNS stimulation.
  • Parasym Performance

Products and services

  • Nuropod A wearable vagus nerve stimulator designed to reduce stress by delivering gentle electrical pulses through electrodes placed on the left tragus of the ear. It stimulates the vagus nerve to enhance recovery, autonomic nervous system regulation, HRV improvement, sleep quality, and inflammation reduction.
  • Parasym Performance A sub-brand offering focused on performance optimization, enabling users to command calm and perform on demand through targeted vagus nerve stimulation for athletes and high performers seeking enhanced recovery and autonomic regulation.

Quantifiable outcome

  • 57% improvement in learning acquisition (long-term retention of learned second-language vocabulary at 7-day recall vs. placebo)
  • +4 more outcomes

Companies that use Parasym

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Parasym technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Parasym partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • UCLAcoreStrategic or Co-development PartnerParasym developed its Nuropod vagus nerve stimulation technology in partnership with UCLA, one of the world's leading research universities. UCLA's involvement provides academic credibility and research infrastructure supporting the device's clinical validation.
  • University of ChicagocoreStrategic or Co-development PartnerParasym developed its technology in partnership with the University of Chicago, contributing research expertise to the clinical validation of its auricular vagus nerve stimulation device.
  • 150+ Elite Research InstitutionscoreStrategic or Co-development PartnerParasym is trusted by 150+ internationally recognized institutions that serve as research and clinical trial partners. These partnerships span elite universities, sports organizations, and national programs. The company conducts 100+ ongoing clinical studies across all major health and performance applications through these partnerships.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Parasym competitors and assessment

Company assessment

Direct peers

  • electroCore: electroCore manufactures gammaCore, a non-invasive vagus nerve stimulation (nVNS) device cleared for migraine, cluster headache, and certain autonomic indications. It is the closest direct competitor to Parasym in portable, non-invasive VNS hardware and is pursuing overlapping clinical and consumer applications.
  • Neuvana: Neuvana markets a consumer non-invasive vagus nerve stimulation earbud product aimed at stress relief, relaxation, and focus. It is the closest direct peer to Parasym on the consumer/aVNS side, with a similar product form factor and stress/wellness value proposition.
  • Apollo Neuroscience: Apollo Neuroscience builds a wearable device that uses gentle vibrations to influence the autonomic nervous system, targeting stress, sleep, and focus. It targets the same primary consumer segment (stress and HRV regulation) as Parasym and competes for the same DTC wellness buyer.

Broad incumbents

  • LivaNova (VNS Therapy): LivaNova's VNS Therapy is the established, implanted vagus nerve stimulation system for drug-resistant epilepsy and depression. It is the broad incumbent in the VNS category and defines the surgical standard that Parasym's non-invasive platform positions against.

Emerging players

  • Cefaly: Cefaly produces an external trigeminal nerve stimulation device FDA-cleared for migraine prevention and acute treatment. It is an emerging player in the consumer-prescription neurostimulation space, with overlapping non-invasive cranial stimulation use cases and customer profiles.
  • Muse (Interaxon): Muse produces a consumer EEG brain-sensing headband for meditation, focus, and sleep. It is an emerging player in the consumer neurotechnology category, addressing overlapping mental wellness and nervous system regulation outcomes for a similar affluent wellness buyer.
  • Dreem: Dreem builds a sleep-focused EEG headband with neurofeedback and stimulation capabilities, targeting sleep quality and stress reduction. It is an emerging player in consumer neurotechnology, with overlapping use cases in sleep, HRV, and nervous system regulation that intersect with Parasym's value proposition.

Others

  • WHOOP: WHOOP is a performance wearable focused on recovery, strain, sleep, and HRV tracking, with strong penetration into professional sports and high-performance consumers. It is adjacent to Parasym, competing for the same elite-athlete and high-performer wallet but via biometric tracking rather than neurostimulation.
  • Oura: Oura produces a smart ring focused on sleep, readiness, HRV, and stress insights for consumers and enterprise wellness programs. It is adjacent infrastructure for the same consumer stress/wellness category and competes for placement in employer benefit and performance programs.
  • Therabody: Therabody (maker of Theragun percussive therapy devices) sells recovery and performance hardware into the same elite sports, fitness, and high-performer customer base as Parasym. It is an adjacent recovery-tech brand rather than a direct competitor, but it competes for the same performance dollar.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Parasym social profiles

Digital presence

Parasym financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Parasym leadership team

Management profile

Number of profiles

Profiles2 records

Parasym funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Parasym M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parasym

What does Parasym do?

Parasym develops and sells non-invasive wearable auricular vagus nerve stimulation (aVNS) devices, with the flagship Nuropod priced at $900. The device delivers gentle electrical pulses via electrodes placed on the left tragus of the ear to modulate the parasympathetic nervous system, targeting stress reduction, recovery, HRV improvement, sleep quality, and inflammation reduction for consumers, athletes, and clinical researchers.

Is Parasym a public or private company?

Parasym is a private company. It is classified as unknown and is currently operating.

When was Parasym founded?

Parasym was founded in 2014. It employs 11 to 50 people.

Where is Parasym based?

Parasym is headquartered in London, United Kingdom, in the Europe region.

How does Parasym make money?

Two revenue lines are on record. Nuropod Device Sales are the primary driver. The others are research and Clinical Access.

Who are Parasym's main competitors?

Direct peers on record are electroCore, Neuvana and Apollo Neuroscience. LivaNova (VNS Therapy) is listed as a broad incumbent. Emerging players are Cefaly, Muse (Interaxon) and Dreem. Others are WHOOP, Oura and Therabody.

Does Parasym have an API?

No public API is recorded for Parasym.

What industry is Parasym in?

Parasym's product category is Wearable Neurostimulation Devices. Its primary akta.pro industry code is CRACAQAL, Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices), with a secondary code of HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageNuropod Auricular Vagal Neuromodulation Device: Clinical Evidence Guide ReleasedParasym released a guide on peer-reviewed clinical evidence for its Nuropod auricular vagus nerve stimulation device. The company reports over 60 studies and more than $10 million in R&D, with heart rate variability increasing by an average of 18% and attention by 11% in clinical trials.24-7 Press ReleaseGBK Brand Bar Celebrates ESPY Week with Annual Pre-ESPY Luxury Lounge & FIFA World Cup Semifinal Viewing Party in New York CityGBK Brand Bar hosted its annual Pre-ESPY Luxury Lounge and FIFA World Cup Semifinal Viewing Party at the 6 Columbus Hotel Penthouse in Manhattan on July 14, 2026, gathering elite athletes, ESPY nominees, celebrities, and premium lifestyle brands for networking and a live viewing of the World Cup semifinal. The event featured luxury lifestyle partners including InBody, Nuropod by Parasym, Wontech USA, and others showcasing products to attendees. GBK also supported philanthropy through the Swim Up Hill Foundation & Soweto Swim School, which was present to raise awareness for expanding swimming education access in South African townships.GizmodoStressed? Nuropod Says It Can Fix That—by Hacking Your BrainParasym released the Nuropod, a wearable vagus nerve stimulator priced at $900, in the U.S. late last year, with the device designed to reduce stress by stimulating the vagus nerve through electrodes placed on the left tragus. The company claims the technology, which generates a gentle pulsing sensation, is backed by over 60 studies and developed in partnership with research institutions including UCLA and the University of Chicago. The full research body is not publicly available on Parasym's website, with the company directing researchers and healthcare professionals to apply for access.MedicaldailyChoosing the Best Vagus Nerve Stimulation Device for Recovery, Sleep, and HRV ImprovementA new wearable device, Nuropod, developed by Parasym, is designed for athletes to enhance recovery and autonomic nervous system regulation through auricular vagus nerve stimulation. Clinical studies have shown significant improvements in HRV, fatigue, sleep quality, and inflammation markers, supporting its use for consistent daily recovery support.HIT ConsultantParasym Launches Nuropod, a Non-Invasive Vagus Nerve Stimulation DeviceParasym launched Nuropod, the first ear-based, non-surgical vagus nerve stimulation device in the U.S., backed by over 50 clinical studies. The device claims a 61% increase in vagus nerve activity and a 78% decrease in inflammation, and is available for $900.